

PATIENT INFORMATION LEAFLET

SCHEDULING STATUS: **S4**

XELJANZ® 5 mg film-coated tablets

XELJANZ® 10 mg film-coated tablets

Tofacitinib

Contains sugar

Each 5 mg film-coated tablet contains 59,44 mg of lactose monohydrate.

Each 10 mg film-coated tablet contains 118,88 mg of lactose monohydrate.

Read all of this leaflet carefully before you start taking XELJANZ

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist, nurse or other health care provider.
- XELJANZ has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

What is in this leaflet

1. What XELJANZ is and what it is used for
2. What you need to know before you take XELJANZ
3. How to take XELJANZ
4. Possible side effects
5. How to store XELJANZ
6. Contents of the pack and other information

1. What XELJANZ is and what it is used for

XELJANZ is a medicine that contains the active substance tofacitinib.

XELJANZ is used for the treatment of the following inflammatory diseases

- rheumatoid arthritis
- psoriatic arthritis
- ulcerative colitis

Rheumatoid arthritis

XELJANZ is used to treat adult patients with moderate to severe active rheumatoid arthritis, a long-term disease that mainly causes pain and swelling of your joints.

XELJANZ is used together with methotrexate when previous rheumatoid arthritis treatment was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised.

XELJANZ has been shown to reduce pain and swelling of the joints and improve the ability to perform daily activities, when given on its own or together with methotrexate.

Psoriatic arthritis

XELJANZ is used to treat a condition called psoriatic arthritis. This condition is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis you will be first given another medicine to treat your psoriatic arthritis. If you do not respond well enough or the medicine is not tolerated, you may be given XELJANZ to reduce the signs and symptoms of active psoriatic arthritis and improve the ability to perform daily activities.

XELJANZ is used together with methotrexate to treat adult patients with active psoriatic arthritis.

Ulcerative colitis

Ulcerative colitis is an inflammatory disease of the large bowel. XELJANZ is used to reduce the signs and symptoms of ulcerative colitis when you did not respond well enough or were intolerant to previous ulcerative colitis treatment.

2. What you need to know before you take XELJANZ

Do not take XELJANZ

- if you are hypersensitive (allergic) to tofacitinib or any of the other ingredients of XELJANZ
- if you have a severe infection such as bloodstream infection or untreated (active or latent) tuberculosis (TB) in the lungs or any other part of the body. If you have latent TB it means that you do not have active TB but are infected with *Mycobacterium tuberculosis* (bacteria which causes active TB). You may also not feel sick and or have any symptoms if you have latent TB.
- if you have been informed that you have severe liver problems, including cirrhosis (scarring of the liver)
- if you are pregnant or breastfeeding
- if you have HIV (regardless of whether you are taking medication for it or not)

Don't take XELJANZ 10 mg twice daily if you have any of the following conditions:

- Are taking combined hormonal contraceptives or hormone replacement therapy
- Have heart failure (when the heart does not work as well as it should)
- Have had blood clots in the veins
- Have cancer
- Will have or have recently had major surgery

Warnings and precautions

Talk to your doctor or healthcare professional before taking XELJANZ.

Take special care with XELJANZ

- if you think you have an infection or have symptoms of an infection such as fever, sweating, chills, muscle aches, cough, shortness of breath, new phlegm or change in phlegm, weight loss, warm or red or painful skin or sores on your body, difficulty or pain when swallowing, diarrhoea or stomach pain, burning when you urinate or urinating more often than normal, feeling very tired.
- if you notice any painful blisters on your skin, tell your doctor.

- if you have any condition that increases your chance of infection (e.g., diabetes, HIV/AIDS, or a weak immune system)
- if you have any kind of infection, are being treated for any infection, or if you have infections that keep coming back. Tell your doctor immediately if you feel unwell. XELJANZ can reduce your body's ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection.
- If you are aged 65 years and older. There is a higher rate of infections in patients in this age group. Tell your doctor as soon as you notice any signs or symptoms of infections.
- if you have or have a history of tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting XELJANZ and may retest during treatment.
- tell your doctor if you have or may have HIV infection
- if you have or had hepatitis B or hepatitis C (viruses that affect the liver). The virus may become active while you are taking XELJANZ. Your doctor may do blood tests for hepatitis before you start treatment with XELJANZ and while you are taking XELJANZ.
- if you have ever had any type of cancer. XELJANZ may increase your risk of certain cancers. Lymphoma and other cancers (such as lung, breast, melanoma, prostate and pancreatic) have been reported in patients treated with XELJANZ. If you develop cancer while taking XELJANZ your doctor will review whether to stop XELJANZ treatment.
- if you are at high risk of developing skin cancer, your doctor may recommend that you have regular skin examinations while taking XELJANZ
- If you suffer from blood clots. There have been reports of patients treated with XELJANZ who have developed blood clots. Talk to your doctor if you smoke. He / she will also evaluate whether your body weight, age, or problems being mobile will affect your risk to develop blood clots.
- if you have any chronic lung disease. You may also be at higher risk of certain lung problems. Tell your doctor if you notice any breathing difficulties.
- if you have had diverticulitis (a type of inflammation of the large intestine) or ulcers in stomach or intestines (see section 4)
- if you have heart problems, high blood pressure, or high cholesterol

- if you have liver problems
- if you have kidney problems

Additional monitoring tests

Your doctor should perform blood tests before you start taking XELJANZ, and after 4 to 8 weeks of treatment and then every 3 months, to determine if you have a low white blood cell (neutrophil or lymphocyte) count, or a low red blood cell count (anaemia).

You should not receive XELJANZ if your white blood cell (neutrophil or lymphocyte) count or red blood cell count is too low. If needed, your doctor may interrupt your XELJANZ treatment to reduce the risk of infection (white blood cell counts) or anaemia (red blood cell counts).

Your doctor may also perform other tests, for example to check your blood cholesterol levels or monitor the health of your liver. Your doctor should test your cholesterol levels 8 weeks after you start receiving XELJANZ. Your doctor should perform liver tests periodically.

If you are planning to get vaccinated, tell your doctor. Certain types of vaccines should not be given when taking XELJANZ. Before you start XELJANZ, you should be up to date with all recommended vaccinations. Your doctor will decide whether you need to have herpes zoster vaccination.

Children and adolescents

XELJANZ is not recommended for use in children or adolescents under 18 years of age. The safety and benefits of XELJANZ in children or adolescents have not yet been established.

Other medicines and XELJANZ

Always tell your health care provider if you are taking any other medicines. (This includes complementary or traditional medicines.)

XELJANZ may be used in combination with methotrexate or sometimes alone when used to treat rheumatoid arthritis. In general, fewer side effects were seen when XELJANZ was used alone in rheumatoid arthritis.

Some medicines should not be taken with XELJANZ. If taken with XELJANZ, they could alter the level of XELJANZ in your body, and the dose of XELJANZ may require adjustment. You should tell your doctor if you are using medicines (taken by mouth) that contain any of the following active substances:

- antibiotics such as rifampicin, used to treat bacterial infections
- fluconazole, ketoconazole, clotrimazole, itraconazole, and voriconazole, used to treat fungal infections

XELJANZ is not recommended for use with medicines that depress the immune system, including so called targeted biologic (antibody) therapies, such as those that inhibit tumour necrosis factor, interleukin 17, interleukin 12/interleukin 23, anti-integrins, and strong chemical immunosuppressants including azathioprine, mercaptopurine, ciclosporin, and tacrolimus. Taking XELJANZ with these medicines may increase your risk of side effects including infection.

Serious infections may happen more often in people who also take corticosteroids (e.g., prednisone).

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist or other health care provider for advice before taking this medicine.

If you are a woman of childbearing age, you should use effective birth control during treatment with XELJANZ and for at least 4 weeks after the last dose.

XELJANZ must not be used during pregnancy. Tell your doctor right away if you become pregnant while taking XELJANZ.

If you are taking XELJANZ and breastfeeding, you must stop breastfeeding until you talk to your doctor about stopping treatment with XELJANZ.

Driving and using machines

XELJANZ has no or limited effect on your ability to drive or use machines

It is not always possible to predict to what extent XELJANZ may interfere with the daily activities of the patient. Patients should ensure that they do not engage in the above activities until they are aware of the measure to which XELJANZ affects them.

XELJANZ contains lactose

XELJANZ 5 mg film coated tablet contains approximately 59 mg lactose monohydrate in each tablet and XELJANZ 10 mg film coated tablet contains approximately 119 mg lactose monohydrate in each tablet.

XELJANZ may have an effect on the control of your blood sugar if you have diabetes mellitus. Patients with the hereditary conditions of lactose/fructose or galactose intolerance should not take XELJANZ.

3. How to take XELJANZ

Do not share medicines prescribed for you with any other person.

Always take XELJANZ exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

This medicine is provided to you and supervised by a specialised doctor who knows how to treat your condition.

Rheumatoid arthritis

The recommended dose is 5 mg twice a day.

Psoriatic arthritis

The recommended dose is 5 mg twice a day.

Ulcerative colitis

- The recommended dose is 10 mg twice a day for 8 weeks, followed by 5 mg twice a day.
- Your doctor may decide to extend the initial 10 mg twice a day treatment by an additional 8 weeks (16 weeks in total), followed by 5 mg twice a day.
- Your doctor may decide to stop XELJANZ if XELJANZ does not work for you within 16 weeks.
- For patients, who have previously taken biologic medicines to treat ulcerative colitis (such as those that block the activity of tumour necrosis factor in the body) and these medicines did not work, the doctor may decide to continue giving 10 mg twice a day. Your doctor will tell you if this applies to you.
- If maintaining XELJANZ 5 mg twice a day did not work for you, your doctor may decide to increase the dose to 10 mg twice a day.
- If your treatment is interrupted, your doctor may decide to restart your treatment.

Try to take your tablet at the same time every day (one tablet in the morning and one tablet in the evening).

Your doctor may reduce the dose if you have liver or kidney problems or if you are prescribed certain other medicines. Your doctor may also stop treatment temporarily or permanently if blood tests show low white blood cell or red blood cell counts.

XELJANZ is for oral use. You can take XELJANZ with or without food.

Your doctor will tell you how long your treatment with XELJANZ will last.

Do not stop treatment early if you have the impression that the effect of XELJANZ is too strong or too weak, tell your doctor or pharmacist.

If you take more XELJANZ than you should

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

If you forget to take XELJANZ

Do not take a double dose to make up for forgotten individual doses.

Take your next tablet at the usual time and continue as before.

If you stop taking XELJANZ

You should not stop taking XELJANZ without discussing this with your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

XELJANZ can have side effects.

Not all side effects reported for XELJANZ are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking XELJANZ, please consult your health care provider for advice.

If any of the following happens, stop taking XELJANZ and tell your doctor immediately or go to the casualty department at your nearest hospital:

Signs of serious infections include

- blood infection (sepsis)
- fever and chills
- cough
- skin blisters
- stomach-ache
- persistent headaches

Signs of allergic reactions include

- chest tightness
- wheezing
- severe dizziness or light headedness
- swelling of the lips, tongue or throat
- hives (itching or skin rash)

Signs of stomach problems (ulcers or holes in your stomach or intestines) include

- fever
- stomach or abdominal pain
- blood in the stool
- unexplained changes in bowel habits

Holes in stomach or intestines happen most often in people who also take nonsteroidal anti-inflammatory drugs or corticosteroids (e.g., prednisone).

These are all very serious side effects. If you have them, you may have had a serious reaction to XELJANZ. You may need urgent medical attention or hospitalisation.

Tell your doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following:

Frequent side effects:

- lung infection (pneumonia and bronchitis)
- influenza
- shingles (herpes zoster)
- urinary bladder infection (cystitis)
- sinusitis
- infections of nose, throat or the windpipe (nasopharyngitis)
- sore throat (pharyngitis)
- low red blood cell count (anaemia)

- headache
- high blood pressure (hypertension)
- cough
- stomach (belly) pain (which may be from inflammation of the stomach lining)
- vomiting
- diarrhoea
- feeling sick (nausea)
- indigestion
- rash
- skin redness
- joint pain
- fatigue (tiredness)
- increased muscle enzymes in the blood (sign of muscle problems)

These are all serious side effects. You may need urgent medical attention.

Less frequent side effects:

- tuberculosis
- painful inflammation of small pockets in the lining of your intestine (diverticulitis)
- kidney infection
- skin infection
- herpes simplex or cold sores (oral herpes)
- viral infections
- viral infections affecting the gut
- other unusual infections, joint infection
- disseminated tuberculosis involving bones and other organs
- tuberculosis involving the brain and spinal cord, meningitis
- some types of skin cancers (non-melanoma-types)
- low white blood cell counts

- increased cholesterol
- dehydration
- poor sleep
- abnormal sensations (“pins and needles” sensation)
- sinus congestion
- fatty liver
- pain in the muscles and joints
- joint swelling
- tendonitis
- increased liver enzymes in the blood (sign of liver problems)
- blood creatinine increased (a possible sign of kidney problems)
- muscle strain

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects to SAHPRA via the “**6.04 Adverse Drug Reaction Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>. By reporting side effects, you can help provide more information on the safety of XELJANZ.

5. How to store XELJANZ

- Store all medicines out of reach of children.
- Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.
- This medicine does not require any special temperature storage conditions.
- Store in the original package in order to protect from moisture.
- Do not use XELJANZ if you notice the tablets show visible signs of deterioration (for example, are broken or discoloured).

- Return all unused medicines to your pharmacist.
- Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

6. Contents of the pack and other information

What XELJANZ contains

XELJANZ 5 mg and 10 mg film-coated tablets

The active substance is tofacitinib.

Each 5 mg and 10 mg film-coated tablet contains 5 mg and 10 mg of tofacitinib (as tofacitinib citrate).

The other ingredients are

Tablet core

croscarmellose sodium

lactose monohydrate

magnesium stearate

microcrystalline cellulose

Film coat

hypromellose 6cP (E464)

lactose monohydrate

macrogol 3350

titanium dioxide (E171)

triacetin (E1518)

FD&C Blue #2/Indigo Carmine Aluminum Lake (E132) (10 mg strength only)

FD&C Blue #1/Brilliant Blue FCF Aluminum Lake (E133) (10 mg strength only)

What XELJANZ looks like and contents of the pack

XELJANZ 5 mg film-coated tablet is white and round in appearance.

XELJANZ 10 mg film-coated tablet is blue and round in appearance.

XELJANZ 5 mg film-coated tablets

The tablets are provided in blisters containing 14 tablets. Each pack contains 56, 112, or 182 tablets and each bottle contains 60 or 180 tablets.

XELJANZ 10 mg film-coated tablets

The tablets are provided in blisters containing 14 tablets. Each pack contains 56, 112, or 182 tablets and each bottle contains 60 or 180 tablets.

Not all pack sizes may be marketed.

Holder of Certificate of Registration

Pfizer Laboratories (Pty) Ltd

85 Bute Lane

Sandton, 2196

South Africa

Tel: (011) 320 6000/0860 734 937 (Toll-free South Africa)

Registration number

XELJANZ® 5 mg film-coated tablets: 47/3.1/1156

XELJANZ® 10 mg film-coated tablets: 47/3.1/1157

This leaflet was last revised on

Not applicable.